Euro vs US Dollar

Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.

Registrieren

RVMD Revolution Medicines Inc

44,39

0,46 (1,05%)

24 Dez 2024 - Geschlossen

Verzögert um 15 Minuten

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Article too big to display. Click here to view on the SEC website

Revolution Medicines (NASDAQ:RVMD)
Historical Stock Chart
Von Nov 2024 bis Dez 2024

Click Here for more Revolution Medicines Charts.

Revolution Medicines (NASDAQ:RVMD)
Historical Stock Chart
Von Dez 2023 bis Dez 2024

Click Here for more Revolution Medicines Charts.

News Revolution Medicines Inc

Revolution Medicines Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters' Option to Purchase Additional Shares
Donnerstag 5 Dezember 2024 (3 Wochen vor) • GlobeNewswire Inc.

Revolution Medicines Announces Pricing of Upsized $750.0 Million Public Offering of Common Stock and Pre-Funded Warrants
Mittwoch 4 Dezember 2024 (3 Wochen vor) • GlobeNewswire Inc.

Revolution Medicines Announces Commencement of Public Offering of Common Stock
Montag 2 Dezember 2024 (3 Wochen vor) • GlobeNewswire Inc.

Revolution Medicines Provides Clinical Updates from its RAS(ON) Inhibitor Portfolio
Montag 2 Dezember 2024 (3 Wochen vor) • GlobeNewswire Inc.

Revolution Medicines to Host RAS(ON) Inhibitor Clinical Update Webcast on December 2, 2024
Mittwoch 27 November 2024 (4 Wochen vor) • GlobeNewswire Inc.

Revolution Medicines Reports Third Quarter 2024 Financial Results and Update on Corporate Progress
Mittwoch 6 November 2024 (2 Monate vor) • GlobeNewswire Inc.

Revolution Medicines to Participate in Upcoming Investor Conferences
Dienstag 5 November 2024 (2 Monate vor) • GlobeNewswire Inc.

Revolution Medicines to Report Financial Results for Third Quarter 2024 After Market Close on November 6, 2024
Mittwoch 30 Oktober 2024 (2 Monate vor) • GlobeNewswire Inc.

Revolution Medicines Presents Initial Data from RMC-9805 Monotherapy Study in Patients with Advanced Pancreatic Ductal Adenocarcinoma
Freitag 25 Oktober 2024 (2 Monate vor) • GlobeNewswire Inc.

Revolution Medicines Presents Updated Data from RMC-6236 Monotherapy Study in Patients with Advanced Pancreatic Ductal Adenocarcinoma
Mittwoch 23 Oktober 2024 (2 Monate vor) • GlobeNewswire Inc.

Revolution Medicines Announces First Patient Dosed in Phase 3 Study Evaluating RMC-6236 in Previously Treated Patients with Metastatic Pancreatic Ductal Adenocarcinoma
Montag 21 Oktober 2024 (2 Monate vor) • GlobeNewswire Inc.

Revolution Medicines to Deliver Multiple Presentations at the 2024 AACR-NCI-EORTC Symposium and Host Investor Webcast
Montag 7 Oktober 2024 (3 Monate vor) • GlobeNewswire Inc.

Weitere Revolution Medicines Inc News-Artikel

Gold vs US Dollar

JP Morgan Chase

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen